Funding will enable completion of ongoing Phase 2 ophthalmology trial and Phase 1/2 neuroinflammation trial.
Company Description
Ashvattha Therapeutics is a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target and reprogram activated cells in regions of inflammation.